IRVINE, Calif.–(BUSINESS WIRE)–Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that 2019 has been its best sales year in company history. Also, the company announced that the fourth quarter of 2019 (current quarter) has already been the best-performing quarter for the company to date.
“The momentum we developed throughout 2019 has helped us exceed expectations,” said Chris MacDuff, Biogennix’s CEO. “Our flagship product Morpheus continues to fuel the company’s growth and is fast becoming the preferred moldable grafting solution to surgeons nationwide. With thousands of cases performed since its commercial launch, we have a large amount of clinical experience with Morpheus and can lean on the product’s clinical efficacy and proprietary TrelCorTM technology. The product has optimal handling and an ideal resorption profile that really resonates with our surgeon users.”
MacDuff added that a number of other factors contributed to Biogennix’s successful year, including the FDA clearance and launch of its new collagen enhanced moldable bone grafting product AgilonTM, continued sales focus, increased manufacturing and R&D capabilities, and successful exhibitions of its proprietary TrelCor technology at key industry events such as NASS. MacDuff concluded saying, “This growth would not have been possible without the hard work of our excellent distributor partners.”
“We are very proud of the growth we saw throughout 2019,” said Michael Roux, Biogennix’s General Manager. “This team works incredibly hard and it’s rewarding to see these results. We enjoy working closely with our customers to develop impactful bone grafting solutions and are excited to continue introducing new solutions to our portfolio in 2020 and beyond.”
Biogennix TrelCor technology is a proprietary material engineered for optimal osteoconductivity and bone regeneration. TrelCor technology provides full interconnected porosity within calcium phosphate/calcium carbonate composite (CP/CC) granules. The interconnected pores mimic the natural blueprint of human cancellous bone, making it attractive for bone cells to grow and proliferate. TrelCor technology has been implanted in thousands of patients since its initial market release in 2011.
Biogennix is a leading developer of osteobiologic products specifically designed for spine fusion and bone trauma. The company is led by a team of scientists and industry veterans committed to delivering unique products for bone regeneration. Biogennix designs, manufactures and distributes all of its products from its Irvine facilities.